Breaking News Instant updates and real-time market news.

ACDO

Accredo Health

$0.00

(0.00%)

, BDX

Becton Dickinson

$253.75

0.45 (0.18%)

04:55
10/07/18
10/07
04:55
10/07/18
04:55

Infection Diseases Society of America (IDSA) to hold a conference

IDWeek 2018 will be held in San Francisco on October 3-7.

ACDO

Accredo Health

$0.00

(0.00%)

BDX

Becton Dickinson

$253.75

0.45 (0.18%)

DNA

Bought by RHHBY

$0.00

(0.00%)

DVAX

Dynavax

$10.60

-0.41 (-3.72%)

ECL

Ecolab

$157.48

1.38 (0.88%)

GILD

Gilead

$76.25

-0.3 (-0.39%)

GSK

GlaxoSmithKline

$39.81

-0.35 (-0.87%)

HZNP

Horizon Pharma

$18.89

-0.05 (-0.26%)

OXFD

Oxford Immunotec

$16.05

0.03 (0.19%)

WTKWY

Wolters Kluwer

$0.00

(0.00%)

TTPH

Tetraphase

$2.56

-0.04 (-1.54%)

SYN

Synthetic Biologics

$2.15

-0.19 (-8.12%)

MRK

Merck

$71.03

-0.17 (-0.24%)

MCRB

Seres Therapeutics

$7.01

-0.3 (-4.10%)

SHPG

Shire

$173.24

-3.54 (-2.00%)

RHHBY

Roche

$0.00

(0.00%)

LMNX

Luminex

$27.86

0.07 (0.25%)

PLCM

bought by Siris Capital 9/16

$0.00

(0.00%)

PFE

Pfizer

$44.91

0.19 (0.42%)

INSM

Insmed

$17.26

-0.95 (-5.22%)

  • 08

    Oct

  • 09

    Oct

  • 10

    Oct

  • 16

    Oct

  • 17

    Oct

  • 17

    Oct

  • 19

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 06

    Nov

  • 27

    Nov

  • 21

    Dec

  • 24

    Dec

  • 11

    Jan

  • 16

    Feb

ACDO Accredo Health
$0.00

(0.00%)

BDX Becton Dickinson
$253.75

0.45 (0.18%)

09/06/18
WELS
09/06/18
NO CHANGE
Target $290
WELS
Outperform
Becton Dickinson price target raised to $290 form $275 at Wells Fargo
Wells Fargo analyst Larry Biegelsen raised his price target for Becton Dickinson to $290 from $275 based on a blend of P/E and EV/EBITDA multiples to reflect increased peer group valuation. After hosting the company's management, the analyst believes that it has a good line of sight into key businesses and is confident in delivering 7% top-line growth in Q4. Biegelsen reiterates an Outperform rating on the shares.
10/04/18
MSCO
10/04/18
NO CHANGE
Target $280
MSCO
Equal Weight
Becton Dickinson price target raised to $280 from $250 at Morgan Stanley
Morgan Stanley analyst David Lewis expects Becton Dickinson will guide FY19 revenue growth to 5%-6% during its upcoming Q4 earnings, which he believes "seems achievable if not conservative." Management is also likely to introduce revenue synergy guidance which should be higher, Lewis predicted. However, he thinks Becton's reported earnings guidance is likely to come in below the Street consensus. Lewis raised his price target on Becton Dickinson shares to $280 to reflect a roll forward to CY20 estimates and he keeps an Equal Weight rating on the stock.
06/21/18
06/21/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. PayPal (PYPL) upgraded to Overweight from Neutral at Atlantic Equities with analyst Kunaal Malde saying he believes the company's differentiated checkout experience should enable the company to continue taking share. 2. Verizon (VZ) and Charter (CHTR) were upgraded to Buy from Neutral at Goldman Sachs. 3. Terex (TEX) upgraded to Buy from Hold at Jefferies with analyst Stephen Volkmann saying Terex has underperformed both the S&P 500 Index and machinery peers year-to-date despite improving backlog and visibility into 2019. 4. AMC Entertainment (AMC) upgraded to Buy from Hold at Benchmark with analyst Mike Hickey saying he believes the company's new movie subscription service will succeed in driving incremental attendance and EBITDA. 5. Becton Dickinson (BDX) upgraded to Overweight from Neutral at JPMorgan with analyst Robbie Marcus saying he sees a "clear path" for Becton to exceed expectations for the second half of 2018 and fiscal 2019 now that the Bard acquisition is two quarters in. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/10/18
ADAM
09/10/18
NO CHANGE
Target $80
ADAM
Buy
Quidel could draw interest from a larger company, says Canaccord
Canaccord analyst Mark Massaro remains positive on Quidel (QDEL) after hosting meetings with management. The analyst cited rising demand for its new products and he expects the company to continue to take market share from larger companies Alere (ABT) and Becton Dickinson (BDX). He also believes the company could draw interest from a larger company, like the bid Alere got from Abbott. Massaro reiterated his Buy rating and raised his price target to $80 from $78 on Quidel shares.
DNA Bought by RHHBY
$0.00

(0.00%)

10/13/17
KEYB
10/13/17
NO CHANGE
Target $106
KEYB
Overweight
Auto suppliers supported by stronger Euro and rising EU output, says KeyBanc
KeyBanc analyst Brett Hoselton raised his profit targets on several auto suppliers, maintaining a positive view on the group overall heading into Q3 earnings. Hoselton says the outlook for the quarter is intact, as lower than expected production of light vehicles was in part offset by stronger EU output. He also cites FX tailwinds, with the Euro have appreciated about 7% sequentially and further supporting revenue in Q3 and possibly FY18. Hoselton raised his profit targets on Delphi Automotive (DLPH) to $106 from $100, Magna International (MGA) to $59 from $55, Lear Corp (LEA) to $184 from $180, and BorgWarner (BWA) to $56 from $50, maintaining an Overweight rating on all these stocks. The analyst is especially bullish on Dana Inc (DNA) given the recent upward revisions to North America Class 8 production, but says his Sector Weight rating reflects the stock prices.
DVAX Dynavax
$10.60

-0.41 (-3.72%)

08/07/18
CANT
08/07/18
NO CHANGE
Target $30
CANT
Overweight
Dynavax price target raised to $30 from $27 at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros raised his price target for Dynavax Technologies to $30 and reiterates an Overweight rating on the shares following the company's Q2 results. The analyst believes there are a "number of opportunities in the near future for Dynavax that could lead to upside for the company," including future Heplisav-B vaccine sales and a Phase 3 trial initiation for SD-101 in advanced melanoma.
05/17/18
JPMS
05/17/18
NO CHANGE
JPMS
Overweight
Dynavax should trade to $21-$22 on abstract data, says JPMorgan
JPMorgan analyst Anupam Rama believes shares of Dynavax should trade up 5%-15% to the $21-$22 range on the SD-101 melanoma ASCO abstract. While some on the Street were inappropriately setting the benchmark at 70%-80% overall response, the abstract data "very much put the early efficacy signals" of SD-101 plus pembrolizumab in the ballpark of nivolumab plus ipilimumab from CHECKMATE-067, with a cleaner safety profile, Rama tells investors in a research note. He says the abstract met his "base case / win / upside scenario."
05/10/18
JPMS
05/10/18
UPGRADE
Target $27
JPMS
Overweight
Dynavax upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Anupam Rama upgraded Dynavax Technologies to Overweight and raised his price target for the shares to $27 from $25 following the company's Q1 results. The analyst believes TLR9 agonist SD-101 is an underappreciated asset.
05/10/18
JPMS
05/10/18
UPGRADE
Target $27
JPMS
Overweight
JPMorgan upgrades Dynavax on 'vastly underappreciated' SD-101
JPMorgan analyst Anupam Rama upgraded Dynavax Technologies to Overweight from Neutral and raised his price target for the shares to $27 from $25. While a Heplisav launch inflection in 2019 is widely expected, the company's SD-101 opportunity is being "vastly underappreciated" at current share levels, Rama tells investors in a research note. SD-101 has shown encouraging early signals of efficacy in both the melanoma and head and neck indications, the analyst contends. Rama points out that a Phase 2 melanoma update is expected next month at ASCO. He likes the stocks' reward/risk profile going into the readout. The analyst sees 30%-60% upside potential versus 0%-10% downside risk on the data.
ECL Ecolab
$157.48

1.38 (0.88%)

06/22/18
JPMS
06/22/18
DOWNGRADE
Target $135
JPMS
Underweight
JPMorgan downgrades Ecolab to Underweight on new earnings pressure
JPMorgan analyst Jeffrey Zekauskas downgraded Ecolab to Underweight and lowered his price target for the shares to $135 from $146. Earnings expectations for Ecolab are likely to move lower due to the effects of the recent strengthening of the U.S. dollar versus offshore currencies, Zekauskas tells investors in a research note. In addition, oil prices have risen sharply over the past quarter, which can bring added earnings pressure in Q3, the analyst adds. As such, Zekauskas thinks it will be difficult for Ecolab's valuation to expand. The stock's "premium" valuation, coupled with the new earnings pressure, makes for an unfavorable risk/reward balance, the analyst contends.
05/07/18
OPCO
05/07/18
NO CHANGE
Target $153
OPCO
Outperform
Ecolab price target raised to $153 from $141 at Oppenheimer
Oppenheimer analyst Scott Schneeberger raised his price target for Ecolab to $153 from $141, citing "solid" Q1 performance/updated 2018 EPS guidance. The analyst reiterates an Outperform rating on the shares.
06/22/18
JPMS
06/22/18
DOWNGRADE
Target $135
JPMS
Underweight
Ecolab downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Jeffrey Zekauskas downgraded Ecolab to Underweight and lowered his price target for the shares to $135 from $146.
08/01/18
JPMS
08/01/18
UPGRADE
Target $147
JPMS
Neutral
Ecolab upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Jeffrey Zekauskas upgraded Ecolab to Neutral and raised his price target for the shares to $147 from $135. The analyst cites valuation for the upgrade and believes market expectations are for the company's financial performance are now more realistic.
GILD Gilead
$76.25

-0.3 (-0.39%)

10/02/18
JEFF
10/02/18
NO CHANGE
Target $135
JEFF
Buy
Jefferies sees Intercept moving higher after 'mixed' Gilead data
Jefferies analyst Michael Yee views Gilead Sciences' (GILD) new six-month nonalcoholic steatohepatitis data as "mixed and undifferentiated." As such, he thinks shares of Intercept Pharmaceuticals (ICPT) probably continue to move higher. The stock is likely to retrace back up into year-end and the first half of 2019 as Street realizes Intercept's Phase III will be positive and de-risked, Yee tells investors in a research note. He says the company has had various competitor Farnesoid X receptor data in Phase I/II read out over the past year or and that these have ended up not too differentiated. This has removed some of the competitive overhang on Intercept, the analyst contends. Yee keeps a Buy rating on the shares with a $135 price target.
10/05/18
SBSH
10/05/18
NO CHANGE
SBSH
Gilead may need Dicerna after Arrowhead, J&J deal, says Citi
Given the partnership announced yesterday between Arrowhead Pharmaceuticals (ARWR) and Johnson & Johnson (JNJ), Gilead Sciences' (GILD) hepatitis B virus portfolio may need another component and Dicerna Pharmaceuticals (DRNA) "could be one of them," Citi analyst Robyn Karnauskas tells investors in a research note. The analyst believes large pharma and Gilead are "still missing a key piece to bring a curative therapy to market that can rapidly and effectively lower HBsAg." The Arrowhead deal makes it apparent that HBV portfolios may need a multi-target approach and validates the RNAi platform to target HBV, the analyst contends.
09/25/18
JEFF
09/25/18
INITIATION
Target $75.5
JEFF
Buy
Cambrex initiated with a Buy at Jefferies
Jefferies analyst David Windley started Cambrex (CBM) with a Buy rating and $75.50 price target. The analyst sees the company, as a leading manufacturer of small molecule active pharmaceutical ingredients, benefiting from increased API outsourcing. He adds that his Gilead (GILD) analysis, Cambrex's top customer, is "differentiated and positive."
10/01/18
CANT
10/01/18
INITIATION
Target $87
CANT
Overweight
Gilead initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young started Gilead Sciences with an Overweight rating and $87 price target.
GSK GlaxoSmithKline
$39.81

-0.35 (-0.87%)

08/15/18
RBCM
08/15/18
NO CHANGE
RBCM
Outperform
RBC says Gilead weakness on CMO leaving, Glaxo data a buying opportunity
RBC Capital analyst Brian Abrahams believes Gilead's (GILD) weakness is potentially due to data from GlaxoSmithKline's (GSK) ATLAS trial and last night's announcement of the departure of its CMO. However, he does not see either as a major fundamental concern and would use the weakness in Gilead shares as a buying opportunity. Feedback he has received from doctors is that injectables like Glaxo's could be used in a select number of patients, but he does not see a major impact on Gilead's HIV franchise near- or long-term from this product, Abrahams said. On the CMO departure, the analyst said that the company clarified that this is "completely unrelated" to the recently-announced CEO transition, so he does not see this reflecting any major structural issue. Abrahams keeps an Outperform rating on Gilead shares, which are down over 3% to $74.82 in afternoon trading.
08/30/18
08/30/18
DOWNGRADE

GlaxoSmithKline downgraded to Hold from Buy at Liberum
Liberum analyst Roger Franklin downgraded GlaxoSmithKline to Hold while raising his price target for the shares to GBP 17 from GBP 16.30. The analyst believes the company's improved research and development is now priced into the shares and he sees less upside going forward.
08/16/18
08/16/18
DOWNGRADE

Hold
AstraZeneca downgraded to Hold following outperformance at Jefferies
As previously reported, Jefferies analyst Ian Hilliker downgraded AstraZeneca (AZN) to Hold from Buy citing valuation following the stock's outperformance since he upgraded it in March. Hilliker has raised his price target on AstraZeneca to 6,200p, but notes that this only leaves about 8% of further upside. Following results for the Q2 period, Hilliker said Novartis (NVS) remains his top European Pharmaceuticals pick, followed by Roche (RHHBY) and GlaxoSmithKline (GSK) in third place.
09/19/18
MSCO
09/19/18
NO CHANGE
MSCO
Equal Weight
Morgan Stanley says AbbVie market cap fell more than largest drug settlement
After AbbVie (ABBV) slid about 3% yesterday following a California Insurance Commissioner lawsuit alleging Humira kickbacks, Morgan Stanley analyst David Risinger noted its $4B loss in market cap was larger than GlaxoSmithKline's (GSK) previous $3B settlement for violations under the False Claims Act, which he called the biggest ever historical pharma settlement. While Commissioner Dave Jones claims imply that the potential fine for Abbvie could theoretically be more than $3B, Risinger also noted that the company told him it believes the allegations "are completely without merit." He maintains an Equal Weight rating and $100 price target on AbbVie shares.
HZNP Horizon Pharma
$18.89

-0.05 (-0.26%)

08/10/18
MZHO
08/10/18
NO CHANGE
Target $25
MZHO
Buy
Horizon Pharma price target raised to $25 from $18 at Mizuho
Mizuho analyst Irina Koffler raised her price target for Horizon Pharma to $25 to reflect higher estimates for the company's pipeline drug, Teprotumumab, and reduced commercial execution risk. The analyst reiterates a Buy rating on the shares following Horizon's Q2 results.
09/24/18
PIPR
09/24/18
NO CHANGE
Target $25
PIPR
Overweight
Piper reiterates Overweight rating on Horizon Pharma after expert call
After hosting a call featuring an expert focused on thyroid eye disease, also known as Graves' orbitopathy, Piper Jaffray analyst David Amsellem reiterates an Overweight rating on Horizon Pharma with a $25 price target. The analyst says commentary from the expert heightened his confidence that Horizon's teprotumumab "will emerge as a paradigm-shifting option" in the broader thyroid eye disease treatment landscape. The expert views teprotumumab not only as a means of avoiding surgical intervention but also as a potential option in less severe patients who are not necessarily headed for surgery, Amsellem tells investors in a research note. He believes Horizon remains well positioned for long-term annual EBITDA growth "that is solidly in the double-digits."
10/04/18
GSCO
10/04/18
NO CHANGE
Target $26
GSCO
Buy
Horizon Pharma teprotumumab data 'highly encouraging,' says Goldman Sachs
After Horizon Pharma announced 72-week durability data for its phase 2 trial of teprotumumab in treatment of thyroid eye disease, or TED, Goldman Sachs analyst Dana Flanders called the data "highly encouraging" and supportive of the drug being competitive to, and potentially better than, the current medical standard of care. The analyst, who forecasts risk-adjusted sales of greater than $200M by 2025 for teprotumumab, said those estimates are likely still conservative. Flanders reiterates a Buy rating on Horizon shares with a $26 price target.
10/05/18
JMPS
10/05/18
NO CHANGE
Target $22
JMPS
Outperform
Horizon's teprotumumab data 'a game-changer,' says JMP Securities
JMP Securities analyst Donald Ellis called Horizon Pharma's long-term, 72-week data on teprotumumab "a game-changer" that he believes will position the drug as a first-line therapy for treating thyroid eye disease, or TED. Ellis, who foresees a potential filing for teprotumumab in mid-2019 and potential approval in early 2020, keeps an Outperform rating and $22 price target on Horizon Pharma shares.
OXFD Oxford Immunotec
$16.05

0.03 (0.19%)

01/08/18
PIPR
01/08/18
NO CHANGE
PIPR
Qiagen, DiaSorin partnership could be disruptive to TB market, says Piper Jaffray
Piper Jaffray analyst William Quirk notes that Qiagen (QGEN) announced a partnership with DiaSorin to develop an automated QuantiFERONTB test for the LIAISON analyzers, and argues that it could be disruptive to the existing physician office latent TB market. The analyst believes the agreement could put pressure on some of Oxford's (OXFD) business and potentially force the company to sign a similar deal with a different immunoassay provider. Quirk points out that Oxford also announced preliminary Q4 revenue below the Street, and while the company did not explain the weak results, he believes it was from U.S. immigration weakness and China order timing.
09/25/18
PIPR
09/25/18
NO CHANGE
PIPR
Piper Jaffray confident on Oxford path to profitability after Quest deal
Piper Jaffray analyst William Quirk notes that Quest Diagnostics (DGX) announced the acquisition of the U.S. laboratory services business from Oxford Immunotec (OXFD), paying $170M for about $55M in tick-borne disease and TB revenue. The deal streamlines Oxford Immunotec into essentially a kit company with better margins and an opportunity to vie for Qiagen's attractive Quest business, he contends, adding that the TB market has been growing in the mid-teens in the U.S., largely converting existing volume from the skin test to the more accurate IGRA class of assays. Long-term, Quirk believes Oxford's revenue estimates may be more predictable than they have been in the past, and his confidence in the company's path to profitability is improved following the deal announcement.
11/01/17
BARD
11/01/17
NO CHANGE
Target $20
BARD
Outperform
Oxford Immunotec weakness overdone, says Baird
Baird analyst Catherine Ramsey Schulte said the weakness in Oxford Immunotec following yesterday's results was overdone. She noted the U.S. TB revenue came in below expectations due to hurricane and immigration headwinds and several pipeline products were either pushed out or canceled. She continues to believe the set up for 2018 is attractive and believes estimates for the company are conservative. Schulte maintained her Outperform rating and lowered her price target to $20 from $22 on Oxford Immunotec shares.
02/27/18
PIPR
02/27/18
NO CHANGE
Target $15
PIPR
Overweight
Oxford Immunotec guidance 'looks beatable,' says Piper Jaffray
Piper Jaffray analyst William Quirk noted that Oxford Immunotec's Q1 revenue guidance is below consensus expectations, but he believes the company is poised to beat 2018 revenue expectations given TB headwinds that are ending and several tailwinds that are upcoming. He maintains an Overweight rating and $15 price target on Oxford shares.
WTKWY Wolters Kluwer
$0.00

(0.00%)

TTPH Tetraphase
$2.56

-0.04 (-1.54%)

09/20/18
PIPR
09/20/18
NO CHANGE
Target $8
PIPR
Overweight
Tetraphase's XERAVA launch expected in the U.S. near term, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff kept his Overweight rating and $8 price target on Tetraphase after its expected approval of XERAVA for the treatment of complicated intra-abdominal infections with a broad label. The analyst sees the label allowing the use of XERAVA as a "broad-spectrum antibiotic", which he says speaks to the strength of the Phase III data. Tenthoff anticipates the drug to be launched in the U.S. after IDWeek in October and in Europe during early 2019.
08/28/18
RILY
08/28/18
NO CHANGE
Target $7
RILY
Buy
Tetraphase price target raised to $7 from $6 at B. Riley FBR
B. Riley FBR analyst Madhu Kumar raised his price target for Tetraphase Pharmaceuticals to $7 following the FDA approval of Xerava. The drug's broad label and reasonable pricing should support a rapid U.S. launch, Kumar tells investors in a research note. He reiterates a Buy rating on Tetraphase.
08/28/18
HCWC
08/28/18
NO CHANGE
Target $7
HCWC
Buy
Tetraphase price target raised to $7 from $6 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Tetraphase Pharmaceuticals to $7 following the approval of Xerava for the treatment of adults with complicated intra-abdominal infections. A broad label and lower than expected price should drive more rapid uptake and higher market share, Arce tells investors in a research note. The analyst affirms a Buy rating on Tetraphase shares.
09/06/18
WBBS
09/06/18
UPGRADE
WBBS
Buy
Tetraphase upgraded to Buy from Speculative Buy at WBB Securities
SYN Synthetic Biologics
$2.15

-0.19 (-8.12%)

05/18/18
05/18/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. MasterCard (MA) initiated with a Neutral at UBS. 2. AMD (AMD) initiated with an Outperform at Cowen while Intel (INTC) was initiated with a Market Perform. 3. Synthetic Biologics (SYN) initiated with a Buy at H.C. Wainwright. 4. Amneal Pharmaceuticals (AMRX) initiated with a Neutral at JPMorgan. 5. Apollo Commercial (ARI) initiated with a Buy at Deutsche Bank. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/18/18
HCWC
05/18/18
INITIATION
Target $1
HCWC
Buy
Synthetic Biologics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Edward White started Synthetic Biologics with a Buy rating and $1 price target. The analyst says his target is based on the outlook of the company's pipeline, which contains ribaxamase, an oral biologic to protect the gut microbiome from IV betalactam antibiotics, that could cause clostridium difficile infection.
05/09/18
GRIF
05/09/18
DOWNGRADE
GRIF
Neutral
Synthetic Biologics downgraded to Neutral from Buy at Griffin Securities
MRK Merck
$71.03

-0.17 (-0.24%)

08/23/18
MSCO
08/23/18
NO CHANGE
Target $74
MSCO
Overweight
Merck price target raised to $74 from $68 at Morgan Stanley
Morgan Stanley analyst David Risinger maintained an Overweight rating on Merck and raised his price target to $74 from $68, citing his expectation for operating leverage to become more visible in 2019 and pipeline progress to improve perception about prospects in the face of Januvia generics in January 2023. Looking ahead, Risinger projects Merck's 5-year CAGR from 2018-2023 for revenue growth of 3% and EPS growth of 8%. Risinger says he believes the primary driver of major pharma stock performance in recent months is "defensive rotation." Looking ahead, the analyst says to watch for U.S. pricing perception drivers in the coming months that could impact pharma stock performance, including potential additional HHS action on drug rebates, November election results and manufacturer communication and action on U.S. list prices by early January.
10/03/18
HCWC
10/03/18
NO CHANGE
Target $4
HCWC
Buy
H.C. Wainwright positive on BioLineRx economic stake increase in BL-8040
H.C. Wainwright analyst Joseph Pantginis notes that BioLineRx (BLRX) announced the increase of its economic stake in BL-8040 from 60% to 80% from Biokine Therapeutics. The analyst believes that this transaction should signal increased confidence to investors as to the company's increased investment into BL-8040. Additionally, Pantginis argues that COMBAT data at ESMO later this month represents a potential tipping point for shares. COMBAT is a Phase 2a open-label study evaluating the safety and efficacy of BL-8040 in combination with pembrolizumab in patients with advanced pancreatic cancer in collaboration with Merck (MRK). He reiterates a Buy rating and $4 price target on BioLineRx shares.
06/28/18
WELS
06/28/18
NO CHANGE
WELS
Wells says Amazon deal, Walgreens results have negative read for drug pricing
After Amazon (AMZN) agreed to acquire online pharmacy PillPack, reportedly for $1B, Wells Fargo analyst David Maris noted that he has long stated that Amazon would enter the pharmacy business and warned about the risk to drug pricing in such a scenario. Maris also noted that Walgreens (WBA) reported its U.S. retail pharmacy comparable store sales fell 1.2% in Q3, adding that retailers tend to push drugmakers on price when they feel pressure and the read-through from its report may be negative for drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/11/18
WELS
07/11/18
NO CHANGE
WELS
Drug stocks may not react favorably to Pfizer price rollback, Trump tweets, says Wells Fargo
Wells Fargo analyst David Maris notes that there was widespread media coverage of drug price increases taken recently by several large cap drug companies, with President Trump criticizing Pfizer (PFE) for taking these price increases. On Tuesday, Pfizer confirmed it was rolling back its July drug price increases following a conversation with President Trump, he adds. Maris believes that drug stocks will not react favorably to this news, given the chilling effect this will likely have on others looking to take price increases. Nonetheless, the analyst points out that the price increases taken in July are only a small number of increases taken over the past year or several years, so the impact of the rollback to the healthcare system is insignificant in the big picture. Other publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
MCRB Seres Therapeutics
$7.01

-0.3 (-4.10%)

08/03/18
08/03/18
DOWNGRADE
Target $6

Underperform
Seres Therapeutics downgraded to Underperform at BofA/Merrill
As previously reported, BofA/Merrill downgraded Seres Therapeutics to Underperform from Neutral and cut its price target to $6 from $13. Analyst Tazeen Ahmad said management has not provided a timeline yet for the ECOSPOR III study of '109 and pushed out his expected launch date to 2021 from 2020. Ahmad believes Seres' microbiome-based pipeline could yield new treatment options for many diseases but notes the landscape is becoming increasingly competitive.
08/03/18
BOFA
08/03/18
DOWNGRADE
BOFA
Underperform
Seres Therapeutics downgraded to Underperform from Neutral at BofA/Merrill
10/12/17
OPCO
10/12/17
INITIATION
Target $19
OPCO
Outperform
Seres Therapeutics initiated with an Outperform at Oppenheimer
Oppenheimer analyst Mark Breidenbach started Seres Therapeutics with an Outperform rating and $19 price target, citing his positive view of the design of the company's Phase 3 SER-109 clinical study and the potential for ecobiotics to secure part of the IBD market.
SHPG Shire
$173.24

-3.54 (-2.00%)

09/07/18
BREN
09/07/18
DOWNGRADE
BREN
Hold
Shire downgraded to Hold from Buy at Berenberg
Berenberg analyst Klara Fernandes downgraded Shire (SHPG) to Hold saying the current valuation offers limited potential upside ahead of the pending takeover by Takeda Pharmaceutical (TKPYY).
09/04/18
09/04/18
DOWNGRADE

Market Perform
Shire downgraded to Market Perform as spread narrows at Bernstein
As previously reported, Bernstein analyst Aaron Gal downgraded Shire (SHPG) to Market Perform from Outperform. The analyst notes that he current controversy on Shire is the risk/reward into the closing of the Takeda (TKPYY) acquisition, and over the past few weeks deal spread narrowed, and the fundamentals have gotten a bit tougher in ADHD, HAE and Hemophilia.
09/04/18
BERN
09/04/18
DOWNGRADE
BERN
Market Perform
Shire downgraded to Market Perform from Outperform at Bernstein
05/09/18
LEER
05/09/18
NO CHANGE
LEER
Takeda/Shire transaction shows path for consolidation, says Leerink
Leerink analyst Geoffrey Porges notes that Takeda (TKPYY) confirmed its intention and agreement to purchase Shire (SHPG) for $62B in cash and stock. For the broader biopharma industry, the analyst believes Takeda's ability to lever up to an estimated 5.4x net debt/EBITDA suggests that investors are underestimating the ability of large cap biopharma companies to pursue large transactions. Nearly all of the large cap biopharma companies face looming growth issues or suffer under revenue-concentration risk discounts that could be mitigated by large-scale acquisitions, he contends. Porges believes that if Takeda can execute the Shire acquisition while checking the boxes of investor demands of a net positive ROIC, instant EPS accretion, maintaining an investment grade credit rating, and massive synergy savings, then others in the biopharma industry with stronger balance sheets and larger valuations can contemplate transactions that are substantially larger even than Shire.
RHHBY Roche
$0.00

(0.00%)

09/17/18
OPCO
09/17/18
NO CHANGE
Target $400
OPCO
Outperform
Roche's AD updates provide favorable read-through for Biogen, says Oppenheimer
Oppenheimer analyst Jay Olson says he remain bullish on Biogen (BIIB), telling investors in a research note that he believes Roche's (RHHBY) Alzheimer's disease updates provide a favorable read-through for Biogen's own Alzheimer's disease portfolio. Among the takeaways from Roche's pipeline update are the importance of a reduction in amyloid, confidence in dose escalation, epidemiology estimate and reimbursement commentary. Olson, who has an Outperform rating and $400 price target on Biogen, says he believes shares are undervalued based on his view that the company's leadership position in neuroscience should deliver long-term growth.
09/21/18
PIPR
09/21/18
NO CHANGE
Target $400
PIPR
Overweight
Biogen upcoming BIIB098 data an overlooked catalyst, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond believes investor sentiment on Biogen (BIIB) overlooks the H2H tolerability data for BIIB098 versus Tecfidera coming in the first half of 2018 Though BIIB098 is largely discounted as an intellectual property play "or worse," the readout, if positive, may be an important catalyst ahead of FDA approval in Q4 of 2019, Raymond tells investors in a research note. He suspects that if BIIB098 shows meaningful tolerability improvement over Tecfidera, "docs will likely take notice." Further, Raymond's new neurologist survey indicates that while the launch trends of Roche's (RHHBY) multiple sclerosis drugOcrevus "appear to be improving," other share trends, including those for Tecfidera and Tysabri, "remain stable." The analyst keeps an Overweight rating on Biogen with a $400 price target.
10/03/18
PIPR
10/03/18
NO CHANGE
PIPR
Overweight
PTC, Roche data add uncertainty to Biogen drug outlook, says Piper Jaffray
The risdiplam spinal muscular atrophy data released this morning by PTC Therapeutic (PTCT) and Roche (RHHBY) stack up fairly well to Biogen's (BIIB) Spinraza clinical data, Piper Jaffray analyst Christopher Raymond tells investors in a research note. Even taking into account all of the usual caveats regarding cross-trial comparisons, risdiplam is shaping up well compared to Spinraza, the analyst contends. He sees the new data as adding uncertainty to the Spinraza trajectory. Nonetheless, Raymond keeps an Overweight rating on shares of Biogen. The analyst made no changes to his Biogen model, but he admits risdiplam, if the data holds up, may impact Spinraza's ultimate market potential. Biogen in midday trading is up 2% to $351.41.
10/03/18
BARD
10/03/18
NO CHANGE
Target $348
BARD
Neutral
Risdiplam data incrementally negative for Biogen, says Baird
Biogen analyst Brian Skorney views this morning's risdiplam data for use in treating spinal muscular atrophy patients as incrementally negative for Biogen (BIIB). The data from PTC Therapeutics (PTCT) and PTC Therapeutics (RHHBY) are compelling so far, and suggest that risdiplam could impact the market share of Biogen's Spinraza, if it comes to market, Skorney tells investors in a research note. He highlights risdiplam's convenience as an oral small molecule and says the Phase II data "continues to impress." The analyst keeps a Neutral rating on Biogen with a $348 price target. The stock in afternoon trading is up $6.90, or 2%, to $352.31.
LMNX Luminex
$27.86

0.07 (0.25%)

09/27/18
PIPR
09/27/18
NO CHANGE
PIPR
Neutral
Piper says about $3.5M of Luminex revenue at risk from Medicare determination
After Palmetto's MolDx released a final local coverage determination that panels of 3-5 pathogens will be covered, but larger panels will not be, Piper Jaffray analyst William Quirk said he believes 51% of the population is covered by MACs that follow MolDX. In terms of the decision's implications for Luminex, Quirk said he sees $3M-$4M in exposure to MolDx Medicare for Luminex's xTAG and Nanosphere tests. He also noted that Luminex management has talked about unbundling to make their panels smaller, which he believes will be the likely outcome. Quirk has a Neutral rating on Luminex shares.
05/07/18
DBAB
05/07/18
UPGRADE
Target $22
DBAB
Hold
Luminex upgraded to Hold from Sell at Deutsche Bank
Deutsche Bank analyst Dan Leonard upgraded Luminex to Hold and raised his price target for the shares to $22 from $19. The analyst views the risk/reward as balanced at current share levels.
PLCM bought by Siris Capital 9/16
$0.00

(0.00%)

PFE Pfizer
$44.91

0.19 (0.42%)

10/02/18
PIPR
10/02/18
NO CHANGE
Target $100
PIPR
Neutral
AbbVie scripts for Humira relatively weak in Q3, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says new survey data from dermatologists and gastroenterologists indicate AbbVie's (ABBV) Humira is losing share faster in psoriasis and inflammatory bowel disease than in rheumatoid arthritis. In that management has called out psoriasis as a key driver of growth, the survey feedback may help explain Humira's relatively weak script trends for Q3, Raymond tells investors in a research note. The analyst believes dermatologists are embracing newer biologics such as Johnson & Johnson's (JNJ) Tremfya while gastroenterologists favor Takeda's Entyvio and increasingly Pfizer's (PFE) Xeljanz. Raymond remains cautious on shares of AbbVie ahead of European biosimilar erosion he expects to start this month. He keeps a Neutral rating on the stock with a $100 price target.
10/01/18
JPMS
10/01/18
NO CHANGE
Target $46
JPMS
Overweight
Pfizer price target raised to $46 from $42 at JPMorgan
JPMorgan analyst Chris Schott raised his price target for Pfizer to $46 on a revisit of the company's story. The analyst sees a "meaningful shift" in the Pfizer narrative away from potential acquisitions to the company's organic growth prospects post the Lyrica patent expiration in 2019. While he expects the company's growth will slow in 2019/2020, he sees a "distinct re-acceleration" of sales and earnings growth for Pfizer in the 2021-2025 period. Schott believes shares of Pfizer can further re-rate if the Street gains further confidence in its "sustained topline growth and capital deployment opportunities." The analyst keeps an Overweight rating on the shares.
09/18/18
JPMS
09/18/18
NO CHANGE
Target $81
JPMS
Overweight
Market evolving favorably for Ascendis into Phase III results, says JPMorgan
JPMorgan analyst Jessica Fye believes the long-acting growth hormone deficiency competitive landscape is evolving favorably for Ascendis Pharma heading into the Phase III results for the company's TransCon growth hormone in Q1 of 2019. The past 12-24 months has brought emerging clinical issues for all three of the key long-acting competitors, Fye tells investors in a research note. These range from the failure of Versartis (VSAR) at the most extreme, to the missed pivotal trial in adults for Pfizer (PFE) and Opko (OPK), to results that may raise questions around efficacy for Novo (NVO) in adults, Fye contends. The analyst believes these create opportunity for Ascendis, assuming the company is successful in Phase III. She continues to have high conviction in the success of the Phase III trial and keeps an Overweight rating on Ascendis Pharma with an $81 price target.
09/12/18
ADAM
09/12/18
NO CHANGE
Target $87
ADAM
Buy
Exact Sciences price target raised to $87 from $72 at Canaccord
Canaccord analyst Mark Massaro raised his price target on Exact Sciences (EXAS) as he updated his model to include the contribution of Pfizer (PFE) reps. Massaro, who believes the company is well positioned to expand its business and he raised his estimates, reiterated his Buy rating on Exact Sciences shares.
INSM Insmed
$17.26

-0.95 (-5.22%)

10/01/18
FBCO
10/01/18
NO CHANGE
Target $35
FBCO
Outperform
Insmed price target raised to $35 from $33 at Credit Suisse
Credit Suisse analyst Martin Auster notes that Insmed received on-time FDA approval of Arikayce for the treatment of refractory NTM MAC, in line with the FDA AdCom recommendation. In a research note to investors, Auster says approval came with "a few surmountable caveats," including a black box warning on the label, the requirement for a controlled, post-approval clinical trial in front-line NTM MAC and the limitation of Arikayce to refractory patients with limited or no options. Auster, who maintains an Outperform rating and raises his price target to $35 from $33, expects shares to rebound to pre-briefing doc levels.
10/01/18
STFL
10/01/18
NO CHANGE
Target $43
STFL
Buy
Refractory label for Insmed Arikayce expected, black box a surprise, says Stifel
Stifel analyst Adam Walsh notes that Insmed received on-time FDA approval of Arikayce for the refractory NTM MAC population. Highlights included an unexpected black box warning on the label, the analyst notes, adding that he expects no impact on uptake. Additionally, Walsh points out that and WAC pricing of $132K far exceeded his prior $90K estimate. Near-term, he thinks deserved share upside on de-risking approval news may be partially offset by the unanticipated black box and cautious management tone on early launch. Regardless, the analyst sees solid value in the shares at current levels based on the Arikayce refractory opportunity alone, independent of planned future label-expansion possibilities. Walsh reiterates a Buy rating and $43 price target on the stock.
09/19/18
GSCO
09/19/18
NO CHANGE
Target $25
GSCO
Neutral
Insmed price target lowered to $25 from $32 at Goldman Sachs
Goldman Sachs analyst Dana Flanders lowered his price target on Insmed to $25 to reflect the 22% decline in its stock price since August amid the rising uncertainty around the "likelihood of the phase 3 surrogate endpoint of culture conversion to predict clinical benefit" in ALIS study. The analyst is also keeping a Neutral rating on the stock citing his measured ALIS launch expectations, but sees its risk-reward more favorable going into the September 28th PDUFA, anticipating an ultimate approval for ALIS in the refractory setting "based on high unmet need for new treatment options in this orphan indication".
08/08/18
08/08/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. REACTIONS TO TESLA'S TALK OF GOING PRIVATE: Jefferies analyst Philippe Houchois raised his price target for Tesla (TSLA) to $360 from $250 after CEO Elon Musk suggested taking the company private. Going private "feels like the right thing to do," Houchois said. "Distraction or not, the move feels right even if Musk is downplaying how supportive public markets have been," the analyst adds. However, with Tesla unable to take on more debt, Houchois wondered who may fund the potential deal and end up as a new large shareholder. While Morgan Stanley analyst Adam Jonas sympathizes with Elon Musk's argument that Tesla could be better off as a private company, he questioned the feasibility of Musk actually being able to achieve that goal. Taking the company private would assume either that the company is on the verge of generating self-sustaining cash flows or that it can tap into a range of strategic sources of capital not previously at its disposal, said Jonas, who sees strategic value at Tesla but thinks the "LBO math required to support [a price of] $420 is extremely aggressive." MORGAN STANLEY SAYS SOUTHWEST A GOOD FIT FOR BERKSHIRE: Morgan Stanley analyst Kai Pan noted that Berkshire Hathaway (BRK.A) has shifted tone in recent years and become a top three shareholder of the "Big Four" U.S. airlines, including Southwest (LUV). Media reports from Forbes, CNN and others have discussed a possible acquisition by Berkshire of the airline, added Pan. He analyzed a theoretical acquisition and came to the conclusion that Southwest could be a strategic fit for Berkshire and the advantages could also be compelling for the airline. Pan estimates Berkshire could pay a 20-40% premium, or $70-80 per share for Southwest, in such a hypothetical takeover situation. Pan has an Overweight rating and $67 price target on Southwest shares. BARCLAYS POSITIVE ON SNAP GUIDANCE CHANGE: Barclays analyst Ross Sandler views Snap's (SNAP) Q2 results as a "mixed bag," with daily active users 2M below his estimate and revenue $20M above his estimate. More importantly, the change in approach towards guidance is "very welcomed and should help to reduce some of the volatility going forward," Sandler said. He believes this is a "big positive for long-term holders looking to get involved." The analyst kept an Overweight rating on Snap with a $16 price target. WAINWRIGHT SAYS INSMED LIKELY TO BE ACQUIRED: H.C. Wainwright analyst Andrew Fein raised his price target for Insmed (INSM) to $43 from $35 following the 12-2 FDA panel vote in favor of ALIS in refractory nontuberculous mycobacterial patients. Insmed is now likely to be acquired as ALIS "fits well within the pipeline of a number of larger companies," Fein said.

TODAY'S FREE FLY STORIES

02:15
10/17/18
10/17
02:15
10/17/18
02:15
General news
FX Update: The Dollar majors continue to lack direction »

FX Update: The Dollar…

01:40
10/17/18
10/17
01:40
10/17/18
01:40
General news
FX Action: USD-JPY posted a three-session high »

FX Action: USD-JPY posted…

SIBN

SI-BONE

$0.00

(0.00%)

20:54
10/16/18
10/16
20:54
10/16/18
20:54
Syndicate
SI-BONE 7.2M share IPO priced at $15.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

AMX

America Movil, also tag AMOV

$15.77

0.38 (2.47%)

, AMOV

America Movil, also tag AMX

$15.03

(0.00%)

20:44
10/16/18
10/16
20:44
10/16/18
20:44
Earnings
America Movil reports Q3 net income MXN18.96B vs. MXN2.52B last year »

Reports Q3 revenue…

AMX

America Movil, also tag AMOV

$15.77

0.38 (2.47%)

AMOV

America Movil, also tag AMX

$15.03

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABT

Abbott

$70.94

2.22 (3.23%)

, USB

U.S. Bancorp

$50.97

0.44 (0.87%)

20:25
10/16/18
10/16
20:25
10/16/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

ABT

Abbott

$70.94

2.22 (3.23%)

USB

U.S. Bancorp

$50.97

0.44 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 17

    Oct

ADTN

Adtran

$18.15

1.08 (6.33%)

20:24
10/16/18
10/16
20:24
10/16/18
20:24
Earnings
Adtran reports Q3 adjusted EPS 21c, consensus 4c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

WAFD

Washington Federal

$29.75

0.45 (1.54%)

20:02
10/16/18
10/16
20:02
10/16/18
20:02
Earnings
Washington Federal reports Q4 EPS 62c, consensus 62c »

Reports Q4 NII $124.8M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

UNH

UnitedHealth

$272.24

12.44 (4.79%)

19:30
10/16/18
10/16
19:30
10/16/18
19:30
Recommendations
UnitedHealth analyst commentary at Piper Jaffray »

UnitedHealth price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

CDAY

Ceridian

$38.44

1.38 (3.72%)

19:25
10/16/18
10/16
19:25
10/16/18
19:25
Conference/Events
Ceridian to hold a conference »

INSIGHTS 2018 will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

HMC

Honda

$27.70

0.65 (2.40%)

19:07
10/16/18
10/16
19:07
10/16/18
19:07
Periodicals
Honda Aircraft sees higher light jet deliveries next year, Reuters says »

Honda Aircraft co-CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

VALE

Vale

$15.50

0.045 (0.29%)

18:59
10/16/18
10/16
18:59
10/16/18
18:59
Periodicals
Vale plans to use cash flow cautiously going forward, Reuters says »

Vale said it intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VICR

Vicor Corporation

$38.35

1.42 (3.85%)

, NFLX

Netflix

$346.40

13.29 (3.99%)

18:55
10/16/18
10/16
18:55
10/16/18
18:55
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Vicor…

VICR

Vicor Corporation

$38.35

1.42 (3.85%)

NFLX

Netflix

$346.40

13.29 (3.99%)

LRCX

Lam Research

$145.33

2.72 (1.91%)

AMAT

Applied Materials

$34.76

1.33 (3.98%)

UAL

United Continental

$83.51

2.17 (2.67%)

FULT

Fulton Financial

$16.39

0.29 (1.80%)

CSX

CSX

$72.15

1.29 (1.82%)

CREE

Cree

$37.56

2.53 (7.22%)

ROKU

Roku

$63.67

1.97 (3.19%)

IBM

IBM

$145.02

3.9 (2.76%)

UFPI

Universal Forest

$34.08

1.27 (3.87%)

SONC

Sonic

$43.27

-0.03 (-0.07%)

EIGR

Eiger BioPharmaceuticals

$10.88

0.63 (6.15%)

SBH

Sally Beauty

$18.91

0.42 (2.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 18

    Oct

  • 21

    Oct

  • 22

    Oct

  • 06

    Nov

  • 13

    Nov

  • 27

    Nov

  • 12

    Dec

  • 13

    Dec

  • 03

    Mar

NFLX

Netflix

$346.40

13.29 (3.99%)

18:38
10/16/18
10/16
18:38
10/16/18
18:38
Hot Stocks
Netflix says it has a 'long, long runway' in India »

Chief Product Officer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 13

    Nov

CBL

CBL & Associates

$3.52

0.085 (2.48%)

, SHLD

Sears

$0.40

0.09 (29.03%)

18:33
10/16/18
10/16
18:33
10/16/18
18:33
Hot Stocks
CBL Properties updates on redevelopment plan for Sears stores »

CBL Properties (CBL)…

CBL

CBL & Associates

$3.52

0.085 (2.48%)

SHLD

Sears

$0.40

0.09 (29.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

VZ

Verizon

$53.68

0.08 (0.15%)

18:26
10/16/18
10/16
18:26
10/16/18
18:26
Hot Stocks
Verizon says Bay, Gulf counties customers to be credited 3 months of service »

Verizon said that it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 13

    Nov

BMO

Bank of Montreal

$80.19

0.93 (1.17%)

18:09
10/16/18
10/16
18:09
10/16/18
18:09
Periodicals
Bank of Montreal names Wolford investment banking vice chair, Reuters says »

Bank of Montreal has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 24

    Oct

SFTBF

SoftBank

$0.00

(0.00%)

18:02
10/16/18
10/16
18:02
10/16/18
18:02
Periodicals
SoftBank COO says 'anxiously' looking at Saudi Arabia situation, Reuters says »

SoftBank COO Marcelo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

IBM

IBM

$145.02

3.9 (2.76%)

18:01
10/16/18
10/16
18:01
10/16/18
18:01
Hot Stocks
IBM sees growth in cloud overall »

Says incremental cash…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 21

    Oct

  • 22

    Oct

  • 03

    Mar

CELC

Celcuity

$26.90

0.4 (1.51%)

, PBYI

Puma Biotechnology

$42.22

1.17 (2.85%)

17:57
10/16/18
10/16
17:57
10/16/18
17:57
Hot Stocks
Celcuity, Puma Biotechnology and West Cancer Center to conduct Phase 2 trial »

Celcuity (CELC) announced…

CELC

Celcuity

$26.90

0.4 (1.51%)

PBYI

Puma Biotechnology

$42.22

1.17 (2.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 15

    Nov

DVN

Devon Energy

$37.08

0.98 (2.71%)

17:51
10/16/18
10/16
17:51
10/16/18
17:51
Recommendations
Devon Energy analyst commentary at MUFG »

Devon Energy price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIA

Viacom

$36.07

1.11 (3.18%)

, VIAB

Viacom

$32.83

1.05 (3.30%)

17:51
10/16/18
10/16
17:51
10/16/18
17:51
Periodicals
Viacom launches Nickelodeon Chinese Animation Development Project, Variety says »

According to Variety,…

VIA

Viacom

$36.07

1.11 (3.18%)

VIAB

Viacom

$32.83

1.05 (3.30%)

IQ

iQIYI

$25.91

-0.19 (-0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

BHP

BHP Billiton

$48.48

0.38 (0.79%)

17:38
10/16/18
10/16
17:38
10/16/18
17:38
Hot Stocks
BHP Billiton reports Q1 iron ore output 61.4M tons, up 10% from last year »

FY19 guidance for iron…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBER

Uber

$0.00

(0.00%)

17:37
10/16/18
10/16
17:37
10/16/18
17:37
Periodicals
Uber increases junk-bond offering to $2B, Bloomberg says »

Uber has boosted the size…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBM

IBM

$145.02

3.9 (2.76%)

17:32
10/16/18
10/16
17:32
10/16/18
17:32
Hot Stocks
IBM says growth was led by hybrid cloud, analytics and AI, digital and security »

Says remains on track…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 21

    Oct

  • 22

    Oct

  • 03

    Mar

NDAQ

Nasdaq

$81.93

1.91 (2.39%)

, ICE

IntercontinentalExchange

$74.95

2.18 (3.00%)

17:31
10/16/18
10/16
17:31
10/16/18
17:31
Hot Stocks
SEC confirms ruling that Nasdaq, NYSE didn't justify rate increases »

Securities and Exchange…

NDAQ

Nasdaq

$81.93

1.91 (2.39%)

ICE

IntercontinentalExchange

$74.95

2.18 (3.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.